Tryptyr is a drug owned by Alcon Laboratories Inc. It is protected by 4 US drug patents filed in 2025 out of which none have expired yet. Tryptyr's patents will be open to challenges from 28 May, 2029. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 16, 2042. Details of Tryptyr's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11850221 | Ophthalmic pharmaceutical compositions and uses thereof |
Dec, 2042
(17 years from now) | Active |
| US10028920 | Methods for treating occular irritation involving tearing by administering modulators of TRPM8 |
Sep, 2031
(6 years from now) | Active |
| US9433679 | Use of TRMP8 for treating opthalmic diseases or conditions involving tearing |
Sep, 2031
(6 years from now) | Active |
| US9095609 | Ophthalmic composition comprising ws-12 and methods to treat xerophthalmia |
Sep, 2031
(6 years from now) | Active |
FDA has granted several exclusivities to Tryptyr. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Tryptyr, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Tryptyr.
Exclusivity Information
Tryptyr holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2030. Details of Tryptyr's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 28, 2030 |
US patents provide insights into the exclusivity only within the United States, but Tryptyr is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Tryptyr's family patents as well as insights into ongoing legal events on those patents.
Tryptyr's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Tryptyr's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Dec 16, 2042 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Tryptyr Generics:
There are no approved generic versions for Tryptyr as of now.
Alternative Brands for Tryptyr
There are several other brand drugs in the same treatment category as Tryptyr. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
About Tryptyr
Tryptyr is a drug owned by Alcon Laboratories Inc. Tryptyr uses Acoltremon as an active ingredient. Tryptyr was launched by Alcon Labs Inc in 2025.
Approval Date:
Tryptyr was approved by FDA for market use on 28 May, 2025.
NCE-1 date:
NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Tryptyr is 28 May, 2025, its NCE-1 date is estimated to be 28 May, 2029.
Active Ingredient:
Tryptyr uses Acoltremon as the active ingredient. Check out other Drugs and Companies using Acoltremon ingredient
Dosage:
Tryptyr is available in solution/drops form for ophthalmic use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.003% | SOLUTION/DROPS | Prescription | OPHTHALMIC |